Supported by Opella
Chair(s)
Mr Rob Moss, Bureau Member, International Pharmaceutical Federation, Netherlands
Introduction:
Join us during the congress and explore the latest evidence and pharmacy-led approaches in liver care. Aligned with the FIP 2025 theme "Pharmacy Forward: Performance, Collaboration, and Health Transformation," this session brings together leading experts to discuss the evolving role of pharmacy in liver health management.
What You'll Gain:
• Deep insights into Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) - covering epidemiology, diagnosis, risk factors, and treatment approaches
• Practical knowledge on the pharmacist's expanding role in MASLD management
• Valuable perspectives from our multidisciplinary expert panel on liver care and evidence-based hepatoprotection
Programme:
| 13:30 – 13:39 | Welcome and Introduction | |
| Mr Rob Moss, Bureau Member, International Pharmaceutical Federation, Netherlands | |
| 13:39 – 13:54 | Understanding MASLD: Risk Factors, Diagnosis, and Treatment Fundamentals |
| Prof. Norbert Stefan, Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany | |
| 13:54 – 14:09 | MASLD in Pharmacy Practice: Identifying Patient Profiles and Guiding Evidence-Based OTC Interventions |
| Assoc. Prof. Piotr Merks, Department of Pharmacology and Clinical Pharmacology, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Poland | |
| 14:09 – 14:24 | Panel Discussion on Integrating Perspectives |
| Prof. Norbert Stefan, Department of Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany | |
| Assoc. Prof. Piotr Merks, Department of Pharmacology and Clinical Pharmacology, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Poland | |
| Assoc. Prof., Daniel Śliż, III Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland | |
| 14:24 – 14:30 | Key observations and closing remarks |
Identify the epidemiology, risk factors, and diagnostic criteria for Metabolic dysfunction Associated Steatotic Liver Disease (MASLD)
2. Describe current evidence-based treatment approaches and hepatoprotective strategies for MASLD management
3. Recognize the expanded role of pharmacists in the multidisciplinary care team for patients with MASLD
4. Apply practical knowledge gained from expert perspectives to optimize pharmaceutical care for MASLD patients
Take home messages:
1. MASLD is the most prevalent chronic liver disease worldwide, characterized by hepatic steatosis and cardiometabolic risk factors.
2. Pharmacists are essential members of the multidisciplinary team, uniquely positioned to identify high-risk patients and support early MASLD detection.
3. The role of pharmacists in MASLD management is expanding, encompassing screening, prevention, and ongoing patient care support.
4. Essential phospholipids (EPL) represent an evidence-based hepatoprotective OTC treatment, showing significant improvements in hepatic steatosis, fatigue, and glycemic control with sustained benefits.
